January 20, 2021 -- Biotechnology company Turnstone Biologics has acquired Myst Therapeutics, a developer of a novel cell therapy platform.
The acquisition adds a pipeline of proprietary tumor-infiltrating lymphocyte (TIL) technology and programs to Turnstone's portfolio of oncolytic virus candidates, several of which are expected to enter the clinic in 2021. TIL utilizes populations of T cells that are isolated from a patient's own tumor and are expanded and stimulated before being readministered to the patient.
The terms of the deal were not disclosed. Myst CEO TJ Langer will become Turnstone's senior vice president of cell therapy development and external innovation.